Zoetis Announces Pricing of $1.25 Billion of Senior Notes
November 09 2015 - 7:43PM
Business Wire
Zoetis Inc. (NYSE:ZTS) announced today that it has agreed to
sell $1.25 billion of senior notes: $500,000,000 in aggregate
principal amount of 3.450% senior notes due 2020 and $750,000,000
in aggregate principal amount of 4.500% senior notes due 2025, in
an underwritten public offering.
Zoetis intends to use the net proceeds to repay amounts drawn
under its revolving credit facility, which were borrowed to fund
the purchase price for the acquisition of PHARMAQ; to repay the
principal when due of its 1.150% senior notes due 2016 in the
aggregate principal amount of $400 million; and for general
corporate purposes. The offering is expected to close on November
13, 2015, subject to customary closing conditions.
Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays
Capital Inc., Citigroup Global Markets Inc. and J.P. Morgan
Securities LLC are acting as joint book-running managers of the
underwriters. The final prospectus supplement and accompanying
prospectus, when available, may be accessed through the SEC’s
website at www.sec.gov. Alternatively, the issuer, the underwriters
or any dealer participating in the offering will arrange to send
you the prospectus and prospectus supplement if you request it by
calling BofA Merrill Lynch at 1-800-294-1322, Barclays at
1-888-603-5847, Citigroup at 1-800-831-9146 and J.P. Morgan at
212-834-4533.
These securities are offered pursuant to a registration
statement that has become effective under the Securities Act of
1933, as amended. These securities are only offered by means of the
prospectus supplement and prospectus relating to the offering. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any offer or
sale of these securities in any state or other jurisdiction, where
the offer, solicitation or sale of these securities would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company,
dedicated to supporting its customers and their businesses.
Building on more than 60 years of experience in animal health,
Zoetis discovers, develops, manufactures and markets veterinary
vaccines and medicines, complemented by diagnostic products and
genetic tests and supported by a range of services. In 2014, the
company generated annual revenue of $4.8 billion. With
approximately 10,000 employees worldwide at the beginning of 2015,
Zoetis serves veterinarians, livestock producers and people who
raise and care for farm and companion animals with sales of
its products in 120 countries.
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to business plans or
prospects, future operating or financial performance, expectations
regarding products, future use of cash and dividend payments, and
other future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to
risks and uncertainties. If one or more of these risks or
uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ
materially from those contemplated by a forward-looking statement.
Forward-looking statements speak only as of the date on which they
are made. Zoetis expressly disclaims any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in the prospectus supplement and accompanying prospectus under the
caption “Risk Factors” and in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2014, including in the sections
thereof captioned “Forward-Looking Information and Factors That May
Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form
8-K. These filings and subsequent filings are available online at
www.sec.gov, Zoetis’s website, or on request from Zoetis.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151109006903/en/
Zoetis Inc.Media Contacts:Bill
Price1-973-443-2742 (o)william.price@zoetis.comorElinore
White1-973-443-2835 (o)elinore.y.white@zoetis.comorInvestor Contacts:John O'Connor1-973-822-7088
(o)john.oconnor@zoetis.comorSteve Frank1-973-822-7141
(o)steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024